A practical reference on GLP-1 类似物: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-06 and is reviewed periodically as new material appears.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C187H291N45O59 | 按主链与 C18 二酸侧链计算 |
| 分子量 | 约 4113.6 道尔顿 | 游离碱形式，随反离子略有差异 |
| 外观 | 白色至类白色冻干粉末 | 具吸湿性，需干燥保存 |
| 溶解性 | 微溶于水，易溶于碱性缓冲液 | 溶解性随 pH 升高而改善 |
| 等电点 | 约 5.4 | 影响缓冲液选择与聚集倾向 |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
=== Labor concerns === Employees have criticized the company's productivity goals, in which they say volume and speed of work done is prioritized over quality. Labs face staffing shortages and employees say they are overworked. Labcorp has been criticized for its process of having all employees terminated upon hospital laboratory management acquisitions, and making them reapply with LabCorp, thereby losing accrued employee benefits, including employee eligibility for Public Service Loan Forgiveness (PSLF) in the case of non-profit hospitals. In 2024, Labcorp stated that its goal is to "operate the company in a non-union environment." After Labcorp became the manager of laboratories of Legacy Health, outsourced laboratory personnel unionized with the Oregon Federation of Nurses and Health Professionals.
The other common method for introducing the Fmoc group is through 9-fluorenylmethylsuccinimidyl carbonate (Fmoc-OSu), which may itself be obtained by the reaction of Fmoc-Cl with the dicyclohexylammonium salt of N-hydroxysuccinimide. Reacting with 9-fluorenylmethyloxycarbonyl azide (itself made by reacting Fmoc-Cl with sodium azide) in sodium bicarbonate and aqueous dioxane is also a method to install Fmoc group. Because the fluorenyl group is highly fluorescent, certain UV-inactive compounds may be reacted to give the Fmoc derivatives, suitable for analysis by reversed phase HPLC. Analytical uses of Fmoc-Cl that do not use chromatography may be limited by the requirement that excess Fmoc-Cl be removed before an analysis of fluorescence.
==== Concerns ==== Numerous scholars and regulatory bodies have raised concerns over the safety profile of such products. One group of scholars argue that organic solvents introduce compounds into the standardized product that may affect the liver; these compounds are not extracted by water and are consequently largely absent from kava prepared with water. For instance, when compared with water extraction, organic solvents extract vastly larger amounts of flavokavains, compounds associated with adverse reactions to kava that are present in very low concentrations in noble kava, but significant in non-noble. They also point out that chemical solvents and water extract different compounds, and "[t]he extraction process may exclude important modifying constituents soluble only in water". In particular, it has been noted that, unlike traditional water-based preparations, products obtained with the use of organic solvents do not contain glutathione, an important liver-protecting compound. Another group of researchers noted that "the extraction process (aqueous vs. acetone in the two types of preparations) is responsible for the difference in toxicity as extraction of glutathione in addition to the kava lactones is important to provide protection against hepatotoxicity." It has also been argued that kavalactone extracts are often made from low-quality plant material, including the toxic aerial parts of the plant that contain the hepatotoxic alkaloid pipermethystine, non-noble kava varieties, or plants affected by mold.
Sources: en.wikipedia.org
Mylodontidae is a family of extinct South American and North American ground sloths within the suborder Folivora of order Pilosa, living from around 23 million years ago (Mya) to 11,000 years ago. This family is most closely related to another family of extinct ground sloths, Scelidotheriidae, as well as to the extant arboreal two-toed sloths, family Choloepodidae; together these make up the superfamily Mylodontoidea. Phylogenetic analyses based on morphology uncovered the relationship between Mylodontidae and Scelidotheriidae; in fact, the latter was for a time considered a subfamily of mylodontids. However, molecular sequence comparisons were needed for the correct placement of Choloepodidae. These studies have been carried out using mitochondrial DNA sequences as well as with collagen amino acid sequences. The latter results indicate that Choloepodidae is closer to Mylodontidae than Scelidotheriidae is. The only other living sloth family, Bradypodidae (three-toed sloths), belongs to a different sloth radiation, Megatherioidea. The mylodontoids form one of three major radiations of sloths. The discovery of their fossils in caverns associated with human occupation lead some early researchers to theorize that the early humans built corrals when they could procure a young ground sloth, to raise the animal to butchering size. However, radiocarbon dates do not support simultaneous occupation of the site by humans and sloths. Subfossil remains like coproliths, fur and skin have been discovered in some quantities.
== Lobbying == The company engages in lobbying in the United States. It also lobbies the Government of Ontario and House of Commons of Canada through Rubicon Strategy, a firm owned by Progressive Conservative Party of Ontario campaign manager Kory Teneycke. Pfizer lobbied various officials in the Government of British Columbia between April and November 2012, including then-premier Christy Clark, future premier John Horgan, future health minister Adrian Dix, and future deputy premier, minister of public safety and solicitor general Mike Farnworth. Notable lobbying organizations or think tanks to which the company has contributed include BIOTECanada, Bipartisan Policy Center, The Business Council, Business Council for the United Nations, Center on Budget and Policy Priorities, European Federation of Pharmaceutical Industries and Associations, Foundation for the National Institutes of Health, Global Health Council, Innovative Medicines Canada, International Federation of Pharmaceutical Manufacturers & Associations, National Health Council, Pharmaceutical Advertising Advisory Board, Pharmaceutical Research and Manufacturers of America, Reagan-Udall Foundation, U.S. Global Leadership Coalition, and World Economic Forum.
==== Peripheral cancers ==== system Xc- function also plays a role in non-neural cancers. Within the gastrointestinal tract, SLC7A11 is upregulated in esophageal, liver, gastric, colorectal, and pancreatic cancers, and inhibition of SLC7A11 has been shown to inhibit tumor progression, likely through induction of ferroptosis. Outside of the gastrointestinal tract, SLC7A11 expression is increased in prostate cancer, bladder cancer, non-small cell lung carcinoma, and melanoma. Inhibition of SLC7A11 in many of these cancers also shows promise in reducing tumor progression.
=== Kröhnke pyridine synthesis === In the Kröhnke pyridine synthesis, an N-pyridine-substituted methyl ketone is used as the reactant. This compound enters the keto-enol equilibrium and reacts with an enone via a Michael addition. A 1,5-dicarbonyl compound is formed, one carbonyl group of which is replaced by ammonia (or a synthesis equivalent) to form an imine. This intermediate subsequently cyclizes to give a pyridine. The reaction is named after Fritz Kröhnke, who developed it for the preparation of 2,4,6-triarylpyridines and published it in 1961.
Sources: en.wikipedia.org
==== Substrate or product ==== Substrate or product inhibition is where either an enzymes substrate or product also act as an inhibitor. This inhibition may follow the competitive, uncompetitive or mixed patterns. In substrate inhibition there is a progressive decrease in activity at high substrate concentrations, potentially from an enzyme having two competing substrate-binding sites. At low substrate, the high-affinity site is occupied and normal kinetics are followed. However, at higher concentrations, the second inhibitory site becomes occupied, inhibiting the enzyme. Product inhibition (either the enzyme's own product, or a product to an enzyme downstream in its metabolic pathway) is often a regulatory feature in metabolism and can be a form of negative feedback.
=== Chairmen === R.S. Sharma, 1972 - 1977 A.R. Kulkarni, 1978 - 1981 Niharranjan Ray, 1981 - 1981 Lokesh Chandra, 1982 - 1985 Irfan Habib, 1986 - 1993 Ravinder Kumar, 1993 - 1996 S. Settar, 1996 - 1999 K.S. Sarma (acting), 1999 - 1999 B.R. Grover, 1999 - 2001 K.S. Lal, 2001 - 2001 M.G.S. Narayanan, 2001 - 2003 Kumud Bansal (acting), 2003 - 2004 D.N. Tripathi, 2004 - 2007 K.M. Acharya (acting), 2007 - 2007 Sabyasachi Bhattacharya, 4 March 2007 – 3 March 2010 Sabyasachi Bhattacharya (acting), 4 April 2010 – 20 May 2011 Basudev Chatterjee, 20 May 2011 - 2014 Yellapragada Sudershan Rao, 28 June 2014 - 26 June 2017 A.P Jamkhedkar, 15 February 2018 – 14 January 2022 Raghuvendra Tanwar, 14 January 2022 - present
=== Waterways === Scammonden Reservoir, Deanhead Reservoir – both in the moors near Ripponden River Aire, River Calder, River Hebble, River Spen, River Worth Aire and Calder Navigation Calder and Hebble Navigation Huddersfield Broad Canal Huddersfield Narrow Canal, Standedge Tunnel Leeds and Liverpool Canal Rochdale Canal
Sources: en.wikipedia.org
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。
胰岛素释放需要细胞内环腺苷酸与钙信号升高，同时依赖葡萄糖代谢产生的协同信号。血糖水平较低时协同信号不足，分泌增强有限。这一机制在降糖效果与低血糖风险之间提供了缓冲。
白蛋白结合是主要原因，它减少肾小球滤过并保护分子免受蛋白酶降解。序列修饰带来的酶解抵抗同样不可忽略，二者共同作用。脂肪链的疏水性还会影响组织分布，但其对总半衰期的贡献程度仍在研究之中。
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.